Screener
ArriVent BioPharma, Inc. AVBP Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Accounts payable | 2,807 | 582 |
| Accrued expenses | (3,828) | (4,879) |
| Operating lease liabilities | 47 | (4) |
| Net cash used in operating activities | (41,892) | (68,008) |
| Cash flows from investing activities: | ||
| Purchase of short-term and long-term investments | (64,383) | (9,817) |
| Sales and maturities of short-term and long-term investments | 67,965 | 46,638 |
| Net cash used in investing activities | 3,582 | 36,821 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s operating cash flow?
- ArriVent BioPharma, Inc. (AVBP) reported operating cash flow of -$41.89M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s operating cash flow changed year-over-year?
- ArriVent BioPharma, Inc.'s operating cash flow increased by 38.4% year-over-year, from -$68.01M to -$41.89M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s operating cash flow?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s operating cash flow has grown at a 69.6% compound annual growth rate (CAGR), from -$55.84M to -$160.59M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about ArriVent BioPharma, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude